Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
14 nov. 2024 08h00 HE
|
Rani Therapeutics, LLC
- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting...
Rani Therapeutics to Participate in Upcoming Investor Conferences
07 nov. 2024 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Participate in September Investor Conferences
03 sept. 2024 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Participate in August Investor Conferences
29 juil. 2024 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
22 juil. 2024 08h30 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
24 juin 2024 07h00 HE
|
Rani Therapeutics, LLC
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...
Rani Therapeutics to Participate in May Investor Conferences
14 mai 2024 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
06 mai 2024 16h05 HE
|
Rani Therapeutics, LLC
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis...
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
15 mars 2024 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
05 févr. 2024 08h00 HE
|
Rani Therapeutics, LLC
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111...